Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuromuscular ultrasound as a biomarker in the SOD1 mouse model of amyotrophic lateral sclerosis.

PloS one·2026
Same author

Innate immune signaling as a potential pathomechanistic biomarker for distinct subtypes in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Between guidelines and reality: expert neurologists' perspectives on structural resources for ALS care in Germany.

Neurological research and practice·2026
Same author

Multi-modal dissection of cell-type specific TDP-43 pathology in the motor cortex.

Nature communications·2026
Same author

RIG-I Mediated Neuron-Specific IFN Type 1 Signaling in FUS-ALS Induces Neurodegeneration and Offers New Biomarker-Driven Individualized Treatment Options for (FUS-)ALS.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Minimum important slowing of disease progression as determined by the ALS functional rating scale - a survey of patient expectations toward disease-modifying drugs in ALS.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026

Related Experiment Video

Updated: Sep 2, 2025

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

61.4K

Progress in spinal muscular atrophy research.

Claudia Wurster1, Susanne Petri2

  • 1Department of Neurology, Ulm University, Ulm.

Current Opinion in Neurology
|August 9, 2022
PubMed
Summary

New therapies have revolutionized spinal muscular atrophy (SMA) treatment, offering hope for patients. Advances include approved drugs and newborn screening, with future strategies focusing on SMN-independent approaches.

More Related Videos

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.2K
Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons
10:57

Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons

Published on: July 13, 2015

12.8K

Related Experiment Videos

Last Updated: Sep 2, 2025

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

61.4K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.2K
Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons
10:57

Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons

Published on: July 13, 2015

12.8K

Area of Science:

  • Neurology
  • Genetics
  • Molecular Biology

Background:

  • Spinal muscular atrophy (SMA) is a rare genetic disorder affecting motor neurons.
  • The journey to understanding SMA involved clinical descriptions, genetic cause discovery, and molecular mechanisms.

Purpose of the Study:

  • To summarize key clinical and basic science advancements in spinal muscular atrophy.
  • To highlight the evolution of SMA understanding and therapeutic development.

Main Methods:

  • Review of clinical trial data for approved SMA therapies.
  • Analysis of genetic and molecular research findings in SMA.
  • Examination of newborn screening implementation for SMA.

Main Results:

  • FDA approval of nusinersen (2016), onasemnogene abeparvovec-xioi (2019), and risdiplam (2020) for SMA treatment.
  • Demonstrated efficacy of SMN-targeting therapies in clinical trials and real-world settings.
  • Global implementation of newborn screening for SMA.

Conclusions:

  • Significant progress has been made in SMA therapeutics, improving patient outcomes.
  • Current treatments focus on upregulating SMN protein levels.
  • Future research may explore SMN-independent strategies, such as targeting skeletal muscle.